| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$1,495 |
Presentation of Ophthalmology Clinical Trial Data at ARVO
|
4 May 2026 9:14AM |
$1.225 |
$1.520 |
risen by
24.08%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC Therapeutics announced trial data at ARVO conference.
- VP-001 targets Retinitis Pigmentosa type 11 (RP11).
- PYC-001 targets Autosomal Dominant Optic Atrophy (ADOA).
- VP-001 addresses PRPF31 gene haploinsufficiency.
- PYC-001 increases OPA1 protein levels.
- Both drugs show promising safety and efficacy.
- Potential first-in-class treatments for eye diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$402 |
Weekly NTA Update
|
4 May 2026 9:13AM |
$2.820 |
$2.810 |
fallen by
0.35%
|
|
| SSH Group Ltd (SSH) ORDINARY FULLY PAID |
Industrials |
$15 |
Binding Agreement to Acquire Elphinstone Mechanical Services
|
4 May 2026 9:13AM |
$0.180 |
$0.140 |
fallen by
22.22%
|
|
SSH - Price-sensitive ASX Announcement
Full Release
Key Points
- SSH to acquire 100% of Elphinstone Mechanical Services (EMS).
- EMS is an Australian-owned company specializing in mechanical services and workforce solutions for the mining sector.
- The acquisition is expected to be immediately earnings and margin accretive to SSH.
- EMS will continue to operate under its existing brand with its current leadership team.
- The transaction expands SSH's operations into Queensland and the broader east coast of Australia.
- SSH expects to generate significant synergies and efficiencies post-acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$647 |
Proposed issue of securities - IMR
|
4 May 2026 9:12AM |
$1.975 |
$1.830 |
fallen by
7.34%
|
|
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$647 |
Imricor Completes Successful A$60 Million Capital Raise
|
4 May 2026 9:12AM |
$1.975 |
$1.830 |
fallen by
7.34%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor Medical Systems, Inc. successfully raised A$60 million through a placement with new and existing institutional and sophisticated investors.
- The funds will support the launch of NorthStar in the U.S., advance regulatory approvals for the Electrophysiology platform, and complete key clinical programs.
- Approximately A$102.9 million in cash reserves is expected post-placement.
- Placement was completed at an offer price of A$1.85 per CDI, representing a 6.3% discount to the last traded price.
- The completion of the placement positions Imricor to execute on its commercial, clinical, and regulatory objectives.
- Morgans Corporate Limited, Canaccord Genuity (Australia) Limited, and Taylor Collison Limited acted as Joint Lead Managers.
- Steve Wedan, Imricor’s Chair and CEO, emphasized the capital raise will help move from momentum to scale.
- The indicative timetable included trading resumption on 4 May 2026 and settlement of New CDIs on 7 May 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$217 |
VICTORY FINALISES KEY PFS INPUTS
|
4 May 2026 9:12AM |
$1.675 |
$1.650 |
fallen by
1.49%
|
|
VTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Victory Metals Limited has optimized their flotation testwork by using an alternative reagent, reducing costs by approximately 50%.
- The testwork confirmed that the flotation circuit can operate effectively at ambient temperature, eliminating the need for heating systems.
- Tailings management for the North Stanmore project shows promising results with cost-effective dry stacking methods.
- Environmental considerations include the stockpiling of waste and returning tailings to mined pits.
- Victory Metals Limited's tenements are located in the Murchison Province of Western Australia, rich in mining history.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$402 |
Update - Notification of buy-back - RG8
|
4 May 2026 9:12AM |
$2.820 |
$2.810 |
fallen by
0.35%
|
|
| WOTSO (WOT) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$94 |
Update - Notification of buy-back - WOT
|
4 May 2026 9:11AM |
$0.670 |
$0.580 |
fallen by
13.43%
|
|
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$553 |
Update - Notification of buy-back - RG1
|
4 May 2026 9:11AM |
$2.280 |
$2.340 |
risen by
2.63%
|
|
| PM Capital Global Opportunities Fund Limited (PGF) ORDINARY FULLY PAID |
Financials |
$1,494 |
Net Tangible Asset Backing - 1 May 2026
|
4 May 2026 9:11AM |
$2.930 |
$3.110 |
risen by
6.14%
|
|
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$630 |
Weekly NTA 01.05.2026
|
4 May 2026 9:10AM |
$2.610 |
$2.830 |
risen by
8.43%
|
|
| Gorilla Gold Mines Ltd (GG8) ORDINARY FULLY PAID |
Materials |
$242 |
High-Grade Discovery at Sovereign
|
4 May 2026 9:10AM |
$0.360 |
$0.330 |
fallen by
8.33%
|
|
GG8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant high-grade gold discovery at Sovereign Deposit
- 9.3 meters at 20.6g/t Au found in a new footwall position
- Part of the Comet Vale Project in the North Kalgoorlie Gold Hub
- Resource base at the hub is 1.2 million ounces at 3.7 g/t Au
- Sovereign mineralization distinct from typical styles
- GG8's aggressive strategy to discover, define, and develop resources
- Comet Vale strategically located near infrastructure
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Altitude Minerals Ltd (ATT) ORDINARY FULLY PAID |
Materials |
$5 |
Trading Halt
|
4 May 2026 9:10AM |
$0.016 |
$0.011 |
fallen by
31.25%
|
|
ATT - Price-sensitive ASX Announcement
Full Release
Key Points
- Altitude Minerals Ltd requests a trading halt on its securities.
- The halt is pending an announcement regarding a capital raising.
- Trading halt will remain until an announcement or normal trading on 6 May 2026.
- No additional market information required according to the company.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vanadium Resources Limited (VR8) ORDINARY FULLY PAID |
Materials |
$11 |
Proposed issue of securities - VR8
|
4 May 2026 9:09AM |
$0.023 |
$0.016 |
fallen by
30.43%
|
|
| Sunstone Metals Ltd (STM) ORDINARY FULLY PAID |
Materials |
$48 |
Drilling continues to extend Bramaderos mineralisation
|
4 May 2026 9:09AM |
$0.380 |
$0.210 |
fallen by
44.74%
|
|
STM - Price-sensitive ASX Announcement
Full Release
Key Points
- Drilling program continues at Bramaderos Gold-Copper Project.
- Strong assay results from Copete-Porotillo complex extending mineralisation.
- Objective to increase 3.6 Moz AuEq2 Bramaderos Mineral Resource.
- Notable drill intersections: 200m at 0.40 g/t Au-Eq2 and 148.2m at 0.40 g/t Au-Eq2.
- Potential for large-scale resource growth and economic benefits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vanadium Resources Limited (VR8) ORDINARY FULLY PAID |
Materials |
$11 |
US Critical Minerals Development Supported by Placement
|
4 May 2026 9:09AM |
$0.023 |
$0.016 |
fallen by
30.43%
|
|
VR8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Vanadium Resources Limited (VR8) received firm commitments to raise A$1.0 million through a share placement.
- The Placement is to support the development of the Steelpoortdrift Vanadium Project and the V-Iron Plant.
- The V-Iron Plant aims to co-produce vanadium-rich slag and pig iron.
- US Vanadium Holding Company LLC is involved in a non-binding offtake term sheet for 100% of vanadium-bearing slag production.
- Rand Merchant Bank was appointed as the exclusive financial advisor and capital sourcing agent.
- The Steelpoortdrift Project is one of the largest global concentrations of vanadium outside China and Russia.
- Funds will be used for scoping studies, site agreements, and professional costs for strategic funding.
- The V-Iron Plant aligns with Western critical mineral supply chains for defence, commercial, and industrial applications.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Macro Metals Limited (M4M) ORDINARY FULLY PAID |
Materials |
$32 |
NXM: MOU Signed With Mining Contractor to Advance Gold Dep
|
4 May 2026 9:08AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
M4M - Price-sensitive ASX Announcement
Full Release
Key Points
- MOU signed for Crusader-Templar gold deposit development
- Partnership between Nexus Minerals and Macro Gold Mining Services
- MGMS to fund and manage mine development and operations
- Profit sharing agreement: Nexus 60%, MGMS 40%
- MOU includes exclusivity and confidentiality provisions
- Non-binding MOU, aiming for a binding agreement
- Permits for native vegetation clearing obtained
- Project benefits from favorable current gold prices
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID |
Health Care |
$49 |
TRP 8802 delivers 75% breakthrough response in IBS
|
4 May 2026 9:08AM |
$0.037 |
$0.030 |
fallen by
18.92%
|
|
ENP - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 2a clinical trial of TRP-8802 achieved 75% response rate
- Clinical improvements linked to psychological flexibility and insight
- Supports gut-brain axis mechanism of action
- Potential for TRP-8803 development and partnerships
- IBS market in the US exceeds $60 billion annually
- Study involved 12 treatment-resistant IBS patients
- Results presented at Digestive Disease Week 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$553 |
Weekly NTA Update
|
4 May 2026 9:07AM |
$2.280 |
$2.340 |
risen by
2.63%
|
|
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$60 |
Botanix appoints Chief Operating Officer
|
4 May 2026 9:06AM |
$0.027 |
$0.022 |
fallen by
18.52%
|
|
| PT Antam (Persero) Tbk (ATM) CHESS DEPOSITARY INTERESTS 1:5 |
Materials |
$1 |
Reinstatement to Quotation
|
4 May 2026 9:05AM |
$0.960 |
$0.970 |
risen by
1.04%
|
|
ATM - Price-sensitive ASX Announcement
Full Release
Key Points
- The suspension of trading in Aneka Tambang (Persero) Tbk (PT) securities is lifted.
- Reinstatement to quotation effective from 4 May 2026.
- This follows the lodgement of the Annual Report for the financial year ended 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$4 |
Proposed issue of securities - CYP
|
4 May 2026 9:05AM |
$0.323 |
$0.018 |
fallen by
94.42%
|
|
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$4 |
Cynata Secures Commitments for $1.5m Placement
|
4 May 2026 9:05AM |
$0.323 |
$0.018 |
fallen by
94.42%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Cynata Therapeutics Limited has secured firm commitments to raise A$1.5 million via an institutional placement.
- The placement involves issuing approximately 6 million new shares at A$0.25 each, representing a discount to recent trading prices.
- Funds will support commercial partnership pursuits and general working capital post-clinical trial results.
- Phase 3 osteoarthritis and Phase 2 acute graft-versus-host disease trial results are expected in May and June 2026, respectively.
- The placement was managed by Taylor Collison Limited and Euroz Hartleys Limited.
- Cynata's strategy includes minimizing dilution and extending financial runway ahead of trial readouts.
- The company develops therapies using its proprietary Cymerus™ stem cell platform technology.
- Cymerus™ enables the production of mesenchymal stem cells (MSCs) at scale from induced pluripotent stem cells (iPSCs).
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ECS Botanics Holdings Ltd (ECS) ORDINARY FULLY PAID |
Health Care |
$7 |
ECS Investor Presentation
|
4 May 2026 9:05AM |
$0.005 |
$0.005 |
fallen by
10%
|
|
| Dexus Industria REIT (DXI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$774 |
Update - Notification of buy-back - DXI
|
4 May 2026 9:04AM |
$2.490 |
$2.460 |
fallen by
1.20%
|
|
Call 1300 880 160
Start a chat
Schedule a call
